Inactive Instrument

Intrexon Corp Stock Nyse

Equities

US46122T1025

Pharmaceuticals

Sales 2024 * 5.59M Sales 2025 * 45.44M Capitalization 353M
Net income 2024 * -89M Net income 2025 * -73M EV / Sales 2024 * 19.2 x
Net cash position 2024 * 246M Net cash position 2025 * 157M EV / Sales 2025 * 4.32 x
P/E ratio 2024 *
-4.22 x
P/E ratio 2025 *
-6.21 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.7%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 19-12-31
Director of Finance/CFO 62 21-09-30
Chairman 70 08-01-31
Members of the board TitleAgeSince
Chairman 70 08-01-31
Director/Board Member 68 09-02-28
Corporate Officer/Principal 52 14-07-31
More insiders
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Related indices
More about the company